-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Relevant statistics show that more than 40 pharmaceutical companies have released their 2021 annual reports, involving sub-sectors such as medical devices, chemical drugs, medical services, biological products, and pharmaceutical business
.
Among them, 11 medical device companies disclosed performance data, and the overall performance was outstanding
.
From the perspective of net profit growth, Wantai Bio, Leadman, and Yirui Technology's net profit growth rate exceeded 100%, 198.
59%, 143.
97% and 117.
79% respectively
.
Among them, Wantai Bio is an enterprise engaged in the research and development, production and sales of in vitro diagnostic reagents, instruments and vaccines
.
The 2021 annual report shows that the company achieved revenue of 5.
75 billion yuan, a year-on-year increase of 144.
25%; net profit attributable to the parent was 2.
021 billion yuan, a year-on-year increase of nearly 200%
.
Regarding the growth in performance, Wantai Bio said that it was mainly due to the increase in the revenue of bivalent cervical cancer vaccines, reagents and active raw materials, as well as the substantial increase in overseas testing demand, and the company's raw material sales and overseas testing reagent export revenue achieved rapid growth
.
Leadman's 2021 annual report shows that during the reporting period, the company achieved operating income of 564 million yuan, a year-on-year increase of 19.
63%; net profit attributable to shareholders of the listed company was about 22.
42 million yuan; basic earnings per share was 0.
05 yuan
.
The distribution plan is: a cash dividend of 0.
2 yuan (tax included) for every 10 shares, no bonus shares, and no transfer to increase
.
The company is an early in vitro diagnostic product enterprise engaged in the research and development, production and sales of biochemical diagnostic reagents in China.
At present, its main business covers three major fields of in vitro diagnostic reagents, diagnostic instruments and biochemical raw materials
.
Yirui Technology's performance in 2021 also increased significantly, with operating income of 1.
187 billion yuan, a year-on-year increase of 51.
43%; net profit attributable to the parent of 484 million yuan, a year-on-year increase of 117.
79%; basic earnings per share of 6.
67 yuan
.
The company plans to distribute cash dividends of 22 yuan (tax included) for every 10 shares to all shareholders
.
According to the data, Yirui Technology is a digital X-ray detector manufacturer oriented by the technology development trend of the whole industry chain and its technical level is in line with international standards.
It is mainly engaged in the research and development, production, sales and service of digital X-ray detectors, and its products are widely used.
In the fields of medical diagnosis and treatment, industrial non-destructive testing, safety inspection,
etc.
In addition, Huitai Medical performed well
.
In 2021, the company will realize a net profit of 208 million yuan attributable to shareholders of listed companies, a year-on-year increase of 87.
7%
.
At the same time, the company plans to distribute a cash dividend of RMB 10.
00 per 10 shares to all shareholders
.
It is reported that Huitai Medical is an enterprise in the field of electrophysiology and vascular interventional access consumables in China
.
From the perspective of the industry background, in recent years, with the support of a series of favorable national policies and the increase in per capita medical expenditure, China's medical device industry has entered a stage of rapid development
.
Data show that by the end of 2020, the size of China's medical device market was about 772.
1 billion yuan, accounting for about 22% of the global market
.
With the aging of China's population, the continuous development of medical technology, and the continuous improvement of people's health awareness, the medical device industry is expected to maintain rapid growth
.
It is worth mentioning that medical devices are technology-intensive and capital-intensive industries, involving cross-border integration and innovation of multiple disciplines such as medicine, machinery, electronics, materials, and biology, and have relatively high initial capital investment and time investment.
request
.
Therefore, the industry believes that although the market has broad prospects, the entry threshold is relatively high
.
In addition, in recent years, in order to strengthen the supervision and management of medical device production and standardize the development of the medical device industry, relevant departments have issued some new policies and new regulations, and the medical device industry will also usher in stricter supervision
.
Relatively speaking, it is expected that those leading companies with positional advantages are more likely to meet challenges and embrace new market opportunities
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, 11 medical device companies disclosed performance data, and the overall performance was outstanding
.
From the perspective of net profit growth, Wantai Bio, Leadman, and Yirui Technology's net profit growth rate exceeded 100%, 198.
59%, 143.
97% and 117.
79% respectively
.
Among them, Wantai Bio is an enterprise engaged in the research and development, production and sales of in vitro diagnostic reagents, instruments and vaccines
.
The 2021 annual report shows that the company achieved revenue of 5.
75 billion yuan, a year-on-year increase of 144.
25%; net profit attributable to the parent was 2.
021 billion yuan, a year-on-year increase of nearly 200%
.
Regarding the growth in performance, Wantai Bio said that it was mainly due to the increase in the revenue of bivalent cervical cancer vaccines, reagents and active raw materials, as well as the substantial increase in overseas testing demand, and the company's raw material sales and overseas testing reagent export revenue achieved rapid growth
.
Leadman's 2021 annual report shows that during the reporting period, the company achieved operating income of 564 million yuan, a year-on-year increase of 19.
63%; net profit attributable to shareholders of the listed company was about 22.
42 million yuan; basic earnings per share was 0.
05 yuan
.
The distribution plan is: a cash dividend of 0.
2 yuan (tax included) for every 10 shares, no bonus shares, and no transfer to increase
.
The company is an early in vitro diagnostic product enterprise engaged in the research and development, production and sales of biochemical diagnostic reagents in China.
At present, its main business covers three major fields of in vitro diagnostic reagents, diagnostic instruments and biochemical raw materials
.
Yirui Technology's performance in 2021 also increased significantly, with operating income of 1.
187 billion yuan, a year-on-year increase of 51.
43%; net profit attributable to the parent of 484 million yuan, a year-on-year increase of 117.
79%; basic earnings per share of 6.
67 yuan
.
The company plans to distribute cash dividends of 22 yuan (tax included) for every 10 shares to all shareholders
.
According to the data, Yirui Technology is a digital X-ray detector manufacturer oriented by the technology development trend of the whole industry chain and its technical level is in line with international standards.
It is mainly engaged in the research and development, production, sales and service of digital X-ray detectors, and its products are widely used.
In the fields of medical diagnosis and treatment, industrial non-destructive testing, safety inspection,
etc.
In addition, Huitai Medical performed well
.
In 2021, the company will realize a net profit of 208 million yuan attributable to shareholders of listed companies, a year-on-year increase of 87.
7%
.
At the same time, the company plans to distribute a cash dividend of RMB 10.
00 per 10 shares to all shareholders
.
It is reported that Huitai Medical is an enterprise in the field of electrophysiology and vascular interventional access consumables in China
.
From the perspective of the industry background, in recent years, with the support of a series of favorable national policies and the increase in per capita medical expenditure, China's medical device industry has entered a stage of rapid development
.
Data show that by the end of 2020, the size of China's medical device market was about 772.
1 billion yuan, accounting for about 22% of the global market
.
With the aging of China's population, the continuous development of medical technology, and the continuous improvement of people's health awareness, the medical device industry is expected to maintain rapid growth
.
It is worth mentioning that medical devices are technology-intensive and capital-intensive industries, involving cross-border integration and innovation of multiple disciplines such as medicine, machinery, electronics, materials, and biology, and have relatively high initial capital investment and time investment.
request
.
Therefore, the industry believes that although the market has broad prospects, the entry threshold is relatively high
.
In addition, in recent years, in order to strengthen the supervision and management of medical device production and standardize the development of the medical device industry, relevant departments have issued some new policies and new regulations, and the medical device industry will also usher in stricter supervision
.
Relatively speaking, it is expected that those leading companies with positional advantages are more likely to meet challenges and embrace new market opportunities
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
